
ONC-392
Novel antibodies selectively abrogate immune evasion in tumor microenvironment but preserve immune checkpoint against adverse events.
Loading color scheme
From novel biology to clinical stage products.
Best-in-class and first-in-class immunotherapy products targeting cancer evasion of adaptive and innate immunity.
Our team brings success from biotech pharma, and academia to OncoC4.
Novel antibodies selectively abrogate immune evasion in tumor microenvironment but preserve immune checkpoint against adverse events.
Targeting cancer cells through bi-specific antibodies, chimeric antigen receptors T cells (CAR-T), and antibody-drug conjugates (ADC).
OncoC4 has a pipeline of best-in-class and first-in-class immunotherapy products that are moving through preclinical testing.
Developing unique drugs that uncouple therapeutic effects and immunotherapy-related adverse effects.
Scientific discoveries drive explosive immunotherapy.
KENILWORTH, N.J., & ROCKVILLE, Md.--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and OncoImmune, a privately-held, clinical-stage biopharmaceutical company, today announced that the companies have entered into a definitive agreement pursuant to which Merck, through a subsidiary, will acquire all outstanding shares of OncoImmune for an…
OncoImmune, Inc. announced today that it has dosed the first patient in the first-in-human clinical trial of ONC-392, its novel, next generation anti-CTLA-4 antibody, at the University of California (UC) Davis Comprehensive Cancer Center on September 16, 2020.
OncoImmune, Inc. announced today that its Investigational New Drug (“IND”) application for ONC-392, its novel, next generation anti-CTLA-4 antibody, has been approved by the U.S. Food and Drug Administration (“FDA”). The IND approval enables OncoImmune to begin a Phase 1A/1B clinical trial of ONC-392 that is designed to assess the…